The mechanism of action of capmatinib

Capmatinib (Capmatinib), as an innovative targeted therapy drug, is unique in that it can precisely inhibit the activity of MET receptor tyrosine kinase. METgene, as a key gene encoding hepatocyte growth factor receptor, its abnormal activation is closely linked to the occurrence and development of many cancers. Especially in the field of non-small cell lung cancer (NSCLC), METgene mutation or amplification has become an important factor driving cancer progression.

Capmatinib specifically targets MET exon 14 skipping mutations, which are a common driver mutation in patients with non-small cell lung cancer and can lead to abnormal activation of the MET signaling pathway. By specifically blocking the signaling caused by this mutation, capmatinib can effectively inhibit the over-activation of MET, thereby slowing down the proliferation of tumor cells, inhibiting tumor metastasis, and delaying disease progression for patients.

It is worth mentioning that capmatinib has highly selective pharmacological characteristics. It mainly acts on the MET receptor and has less impact on other receptors. This targeting property allows it to reduce damage to healthy cells during the treatment process, thereby significantly reducing the side effects of treatment. Compared with traditional chemotherapy drugs, capmatinib has this advantage.

In addition, capmatinib also has the potential for combination therapy. It can be used in combination with other targeted drugs or chemotherapy drugs to further enhance its efficacy through the interaction of different mechanisms. In patients with MET mutated non-small cell lung cancer, the combination treatment strategy of capmatinib and other drugs has shown a more significant tumor shrinkage effect, bringing new hope for improving the survival rate of patients.

Clinical studies have shown that capmatinib is effective in treating METexon14 non-small cell lung cancer with skipping mutations It has excellent performance in patients and can significantly improve patients' progression-free survival (PFS) and overall survival (OS). In a pivotal clinical trial, capmatinib was even more effective than traditional chemotherapy drugs, especially in patients who had received poor results from other treatments. Therefore, capmatinib has become the first choice targeted therapy drug for the treatment of MET-driven lung cancer due to its unique pharmacological properties.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib